首页> 外文期刊>International journal of clinical rheumatology. >Pleiotropic effects of inflammasome modulation in chronic gout and associated comorbidities: potential therapeutic implications
【24h】

Pleiotropic effects of inflammasome modulation in chronic gout and associated comorbidities: potential therapeutic implications

机译:炎性体调节在慢性痛风和相关合并症中的多效性:潜在的治疗意义

获取原文
获取原文并翻译 | 示例
           

摘要

Gout and hyperuricemia are among the most common inflammatory-metabolic disorders of mankind. Evidence gathered in recent years clearly identifies monosodium urate crystals as exerting a powerful inflammatory stimulus through activation of the inflammasome. Dysregulation of inflammasome function has been implicated in the pathogenesis of a variety of autoinflammatory disorders - so-called inflammasomopathies, including gout, Type 2 diabetes and cancer. Activation of the inflammasome results in the release of proinflammatory cytokines, particularly IL-1, which has been shown to significantly contribute to human disease, and its inhibition has proven of benefit for certain autoinflammatory disorders. The potential therapeutic benefit of inflammasome inhibition with the use of biologic agents used alone or in combination for the therapy of gout is discussed.
机译:痛风和高尿酸血症是人类最常见的炎症-代谢性疾病。近年来收集的证据清楚地表明,尿酸单钠晶体通过激活炎症小体而发挥了强大的炎症刺激作用。炎性体功能失调与多种自身炎性疾病的发病机理有关,这些疾病包括痛风,2型糖尿病和癌症等所谓的炎性同种病。炎性体的活化导致促炎性细胞因子,特别是IL-1的释放,已显示出其对人类疾病的显着贡献,并且其抑制作用已被证明对某些自身炎症性疾病有益。讨论了通过单独使用或联合使用生物制剂治疗痛风时抑制炎症小体的潜在治疗益处。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号